Social entrepreneur, Katy Digovich is Co-founder and CEO of Minutia, an American cell therapy startup working towards the transplant of insulin-producing cells combined with nano-sensors to contribute to a functional cure for Type 1 diabetes.
Digovich’s company, Minutia, is now is working to make beta cells that not only secrete insulin but also know when not to produce insulin when there are already high levels of glucose. An outpatient procedure delivered just below the skin into a Type 1 diabetes patient’s forearm would be a game-changer, since those patients today rely on continuous glucose monitors and manual injections or pumps.
But what spotlights Minutia’s unique approach is what it’s loading into the cells: dozens of golden, star-shaped nano-sensors that sense different variables to monitor the health of the transplanted cells.
Being a Type 1 diabetic herself, Katy has worked in more than 40 countries creating diagnostic and informational tools at the intersection of technology, health, and underserved communities.